PATH
Menu

This fact sheet describes a phase 3 clinical study that PATH and our partners are conducting in Senegal to evaluate the clinical efficacy of a seasonal, trivalent live attenuated influenza vaccine (LAIV). By providing evidence on how well this type of vaccine works among young children in Senegal, this study will help inform efforts in the scientific community to develop optimal LAIVs for the world’s most vulnerable children, as well as policy decisions for potential future LAIV use in Senegal and other tropical, low-resource countries in Africa.

Corporate author(s): PATH

Publication date: May 2013

Available materials

English

French

Investigating Live Attenuated Influenza Vaccine Efficacy in Senegal [French]

120 KB PDF

Also known as: Analyse de l'Efficacité du Vaccin Antigrippal Vivant Atténué au Sénégal

Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.

Region: Africa

See also:

Vaccines and immunizationMiscellaneous

Emerging and epidemic diseasesInfluenza

For more information…

Contact: PATH Publications
Email: publications@path.org
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA